Adherence of Pharmaceutical Advertisements in Medical Journals to FDA Guidelines and Content for Safe Prescribing 英文参考文献.docVIP

下载本文档

2
0
约3.31万字
约 7页
2017-05-11 发布于上海
举报
版权申诉

Adherence of Pharmaceutical Advertisements in Medical Journals to FDA Guidelines and Content for Safe Prescribing 英文参考文献.doc

1、本文档共7页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Adherence of Pharmaceutical Advertisements in Medical Journals to FDA Guidelines and Content for Safe Prescribing 英文参考文献

AdherenceofPharmaceuticalAdvertisementsinMedical JournalstoFDAGuidelinesandContentforSafe Prescribing DeborahKorenstein1*,SalomehKeyhani2,3,AliMendelson4,JosephS.Ross5 1DepartmentofMedicine,MountSinaiSchoolofMedicine,NewYork,NewYork,UnitedStatesofAmerica,2DepartmentofHealthEvidenceandPolicy,MountSinai School ofMedicine,New York, New York, United States ofAmerica, 3HSRDResearch Enhancement Award Program andGeriatrics Research, Education, and Clinical Center,JamesJ.PetersVAMedicalCenter,Bronx,NewYork,UnitedStatesofAmerica,4WeillCornellMedicalCollege,NewYork,NewYork,UnitedStatesofAmerica, 5SectionofGeneralInternalMedicine,DepartmentofMedicine,YaleUniversitySchoolofMedicineandCenterforOutcomesResearchandEvaluation,Yale-NewHaven Hospital,NewHaven,Connecticut,UnitedStatesofAmerica Abstract Background: Physician-directed pharmaceutical advertising is regulated in the United States by the Food and Drug Administration(FDA);adherencetocurrentFDAguidelinesisunknown.Ourobjectivewastodetermineadherenceratesof physician-directedprintadvertisementsinbiomedicaljournalstoFDAguidelinesanddescribecontentimportantforsafe prescribing. MethodsandFindings:Cross-sectionalanalysisofNovember2008pharmaceuticaladvertisementswithintopU.S.-based biomedical journalspublishingoriginalresearch. Weexcludedadvertisementsfor devices,overthecountermedications, and disease awareness. We utilized FDA guideline items identifying unique forms of advertisement bias to categorize advertisementsasadherenttoFDAguidelines,possiblynon-adherenttoatleast1item,ornon-adherenttoatleast1item. Wealsoevaluatedadvertisementcontentimportantforsafeprescribing,includingbenefitquantification,riskinformation and verifiable references. All advertisements were evaluated by 2 or more investigators, with differences resolved by discussion. Twelve journals met inclusion criteria. Nine contained pharmaceutical advertisements, including 192 advertisements for 82 unique products; median 2 per product (range 1–14). Six ‘‘teaser’